Welcome to our dedicated page for ABBVIE news (Ticker: ABBV), a resource for investors and traders seeking the latest updates and insights on ABBVIE stock.
AbbVie Inc. (NYSE: ABBV), headquartered in North Chicago, Illinois, is a leading pharmaceutical company ranked 6th on the list of largest biomedical companies by revenue. Known for their commitment to delivering innovative medicines, AbbVie focuses on several key therapeutic areas including immunology, oncology, neuroscience, and eye care. Their portfolio also includes products and services in aesthetics through Allergan Aesthetics, a company they acquired in 2020.
AbbVie’s flagship product, Humira (adalimumab), generated $21 billion in revenue in 2022, accounting for 37% of the company's total revenues. Humira is approved for the treatment of various autoimmune diseases such as rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis. Beyond Humira, AbbVie has developed other notable immunology drugs, including Skyrizi and Rinvoq, which have shown strong market performance.
In the oncology sector, AbbVie markets Imbruvica and Venclexta, which are critical in treating hematological malignancies. The acquisition of Allergan also brought in new products in aesthetics, including Botox, which is not only a cosmetic treatment but also used therapeutically for various conditions.
AbbVie's research and development efforts are robust, with numerous clinical trials ongoing across its therapeutic areas. Recent achievements include positive topline results from the LEVEL UP study, which demonstrated the efficacy of Rinvoq in treating atopic dermatitis. Financially, AbbVie continues to perform well, reporting first-quarter 2024 revenues of $12.310 billion, a 0.7% increase from the previous year.
Strategic partnerships are also a cornerstone of AbbVie’s growth strategy. Recent collaborations include an agreement with Gilgamesh Pharmaceuticals to develop neuroplastogens for psychiatric disorders and a partnership with Landos Biopharma to enhance their immunology portfolio.
AbbVie remains focused on its mission to address serious health issues and improve patient outcomes globally, leveraging its comprehensive pipeline and innovative solutions in biomedical research.
AbbVie announced positive top-line results from the Phase 3 SELECT-AXIS 2 trial evaluating upadacitinib (RINVOQ) for adults with non-radiographic axial spondyloarthritis. The drug achieved the primary ASAS40 endpoint with 45% of patients responding compared to 23% on placebo (p<0.0001). Significant improvements were also seen in secondary endpoints, including ASDAS Low Disease Activity (42% vs. 18%, p<0.0001). The safety profile was consistent with previous studies, with common adverse events including headache and COVID-19.
AbbVie announced positive top-line results from the Phase 3 SELECT-AXIS 2 trial for RINVOQ (upadacitinib) in patients with active ankylosing spondylitis who had inadequate responses to previous treatments. The study met its primary endpoint with 45% of patients achieving ASAS40 response at week 14 compared to 18% in the placebo group (p<0.0001). Further, RINVOQ demonstrated significant improvements in disease activity and physical functions, with notable reductions in back pain. Safety data were consistent with prior studies, showing no new risks identified.
AbbVie (NYSE: ABBV) is set to release its third-quarter 2021 financial results on October 29, 2021, before market opening. A live webcast of the earnings conference call will occur at 8 a.m. Central time, accessible via AbbVie's Investor Relations website. An archived version will also be available later that day. AbbVie focuses on delivering innovative medicines across various therapeutic areas, including immunology, oncology, and more.
AbbVie announced significant findings on its investigational drugs at the UEG Week Virtual 2021, running from October 3-5. The company will present 13 abstracts, including late-breaking studies on risankizumab (SKYRIZI) for Crohn's disease and upadacitinib (RINVOQ) for ulcerative colitis. Key results from pivotal Phase 3 studies showed upadacitinib's efficacy in symptom control and clinical remission at week 52. Additionally, data highlighting the quality of life improvements for IBD patients will be shared. AbbVie aims to enhance treatment standards in IBD management.
AbbVie has shared new Phase 3 data analyses from the KEEPsAKE-1 and KEEPsAKE-2 studies, detailing the efficacy of risankizumab (SKYRIZI®) in treating adults with active psoriatic arthritis over one year. At the 2021 EADV Virtual Congress, results showed significant patient responses, with 70% and 58% achieving ACR20 response in KEEPsAKE-1 and KEEPsAKE-2, respectively. Furthermore, 76% achieved resolution of dactylitis. The safety profile remained consistent, with no new adverse findings reported. These developments underscore AbbVie's commitment to enhancing treatment options for psoriatic arthritis.
AbbVie (NYSE: ABBV) presented new analyses of its medication RINVOQ® (upadacitinib) for treating moderate to severe atopic dermatitis at the EADV Virtual Congress. Key findings include that over 61% of patients on RINVOQ 30 mg achieved EASI 75 at week 16 compared to 11% on placebo, irrespective of demographics. Additionally, RINVOQ demonstrated superior efficacy against dupilumab in four body regions at week 16. The safety profile remained consistent with previous studies, with acne as the most common adverse event.
AbbVie (NYSE: ABBV) announced FDA approval for QULIPTA™ (atogepant), the first oral CGRP receptor antagonist for preventing episodic migraines in adults. Supported by robust clinical data, QULIPTA demonstrated significant reductions in monthly migraine days and was well tolerated among nearly 2,000 patients in trials. It aims to alleviate the substantial disability caused by migraines, which affect over 39 million people in the U.S. QULIPTA will be available in October 2021, complementing AbbVie's migraine treatment portfolio.
AbbVie (NYSE: ABBV) announced it will present 27 abstracts at the 30th EADV Congress from September 29 to October 2, 2021. Highlights include analyses on RINVOQ (upadacitinib) for atopic dermatitis and new data on SKYRIZI (risankizumab) for psoriasis and psoriatic arthritis. Key findings will come from Phase 3 trials, including a head-to-head study of RINVOQ vs. dupilumab, showcasing safety and efficacy. This reinforces AbbVie's commitment to enhancing care for chronic inflammatory diseases.
AbbVie announced the submission of an application to the FDA for risankizumab-rzaa, a new treatment for moderate to severe Crohn's disease in patients aged 16 and older. This drug, an IL-23 inhibitor, is backed by data from three Phase 3 trials: ADVANCE, MOTIVATE, and FORTIFY. In these studies, patients treated with risankizumab-rzaa showed significantly greater clinical remission and endoscopic response compared to placebo. The therapy aims to address the unmet need for lasting remission in Crohn's patients, as highlighted by AbbVie’s senior VP of research.
FAQ
What is the current stock price of ABBVIE (ABBV)?
What is the market cap of ABBVIE (ABBV)?
What is AbbVie's primary product?
What are the key therapeutic areas AbbVie focuses on?
What significant achievement did AbbVie report in their research efforts?
Who are AbbVie's notable partners?
What are some of AbbVie's key oncology products?
How did AbbVie perform financially in the first quarter of 2024?
What products did AbbVie acquire through Allergan?
What is AbbVie's mission?
What percentage of revenue did Humira contribute in 2022?
Where is AbbVie headquartered?
